87 related articles for article (PubMed ID: 23009996)
1. Exploration of potential ligands against cancer-causing transcription factor E2F3.
Hussain M; Javeed A; Ashraf M; Siddique S; Riaz A; Mukhtar MM
Pak J Pharm Sci; 2012 Oct; 25(4):793-801. PubMed ID: 23009996
[TBL] [Abstract][Full Text] [Related]
2. Importance of molecular computer modeling in anticancer drug development.
Geromichalos GD
J BUON; 2007 Sep; 12 Suppl 1():S101-18. PubMed ID: 17935268
[TBL] [Abstract][Full Text] [Related]
3. Analysis of c-Met kinase domain complexes: a new specific catalytic site receptor model for defining binding modes of ATP-competitive ligands.
Asses Y; Leroux V; Tairi-Kellou S; Dono R; Maina F; Maigret B
Chem Biol Drug Des; 2009 Dec; 74(6):560-70. PubMed ID: 19909299
[TBL] [Abstract][Full Text] [Related]
4. The use of protein-ligand interaction fingerprints in docking.
Brewerton SC
Curr Opin Drug Discov Devel; 2008 May; 11(3):356-64. PubMed ID: 18428089
[TBL] [Abstract][Full Text] [Related]
5. Docking ligands onto binding site representations derived from proteins built by homology modelling.
Schafferhans A; Klebe G
J Mol Biol; 2001 Mar; 307(1):407-27. PubMed ID: 11243828
[TBL] [Abstract][Full Text] [Related]
6. Dinuclear ruthenium(II) triple-stranded helicates: luminescent supramolecular cylinders that bind and coil DNA and exhibit activity against cancer cell lines.
Pascu GI; Hotze AC; Sanchez-Cano C; Kariuki BM; Hannon MJ
Angew Chem Int Ed Engl; 2007; 46(23):4374-8. PubMed ID: 17477461
[No Abstract] [Full Text] [Related]
7. Engineered Thermoplasma acidophilum factor F3 mimics human aminopeptidase N (APN) as a target for anticancer drug development.
Su J; Wang Q; Feng J; Zhang C; Zhu D; Wei T; Xu W; Gu L
Bioorg Med Chem; 2011 May; 19(9):2991-6. PubMed ID: 21493078
[TBL] [Abstract][Full Text] [Related]
8. Structure/function analysis of a dUTPase: catalytic mechanism of a potential chemotherapeutic target.
Harris JM; McIntosh EM; Muscat GE
J Mol Biol; 1999 Apr; 288(2):275-87. PubMed ID: 10329142
[TBL] [Abstract][Full Text] [Related]
9. Binding interaction analysis of the active site and its inhibitors for neuraminidase (N1 subtype) of human influenza virus by the integration of molecular docking, FMO calculation and 3D-QSAR CoMFA modeling.
Zhang Q; Yang J; Liang K; Feng L; Li S; Wan J; Xu X; Yang G; Liu D; Yang S
J Chem Inf Model; 2008 Sep; 48(9):1802-12. PubMed ID: 18707092
[TBL] [Abstract][Full Text] [Related]
10. A phospho-sugar binding domain homologous to NagB enzymes regulates the activity of the central glycolytic genes repressor.
Doan T; Martin L; Zorrilla S; Chaix D; Aymerich S; Labesse G; Declerck N
Proteins; 2008 Jun; 71(4):2038-50. PubMed ID: 18186488
[TBL] [Abstract][Full Text] [Related]
11. Ranking poses in structure-based lead discovery and optimization: current trends in scoring function development.
Rajamani R; Good AC
Curr Opin Drug Discov Devel; 2007 May; 10(3):308-15. PubMed ID: 17554857
[TBL] [Abstract][Full Text] [Related]
12. 3D-QSAR CoMFA analysis of C5 substituted pyrrolotriazines as HER2 (ErbB2) inhibitors.
Awale M; Mohan CG
J Mol Graph Model; 2008 Apr; 26(7):1169-78. PubMed ID: 18055238
[TBL] [Abstract][Full Text] [Related]
13. Toward selective histone deacetylase inhibitor design: homology modeling, docking studies, and molecular dynamics simulations of human class I histone deacetylases.
Wang DF; Helquist P; Wiech NL; Wiest O
J Med Chem; 2005 Nov; 48(22):6936-47. PubMed ID: 16250652
[TBL] [Abstract][Full Text] [Related]
14. Computational sampling of a cryptic drug binding site in a protein receptor: explicit solvent molecular dynamics and inhibitor docking to p38 MAP kinase.
Frembgen-Kesner T; Elcock AH
J Mol Biol; 2006 May; 359(1):202-14. PubMed ID: 16616932
[TBL] [Abstract][Full Text] [Related]
15. Effect of substitution and planarity of the ligand on DNA/BSA interaction, free radical scavenging and cytotoxicity of diamagnetic Ni(II) complexes: a systematic investigation.
Sathyadevi P; Krishnamoorthy P; Butorac RR; Cowley AH; Bhuvanesh NS; Dharmaraj N
Dalton Trans; 2011 Oct; 40(38):9690-702. PubMed ID: 21858314
[TBL] [Abstract][Full Text] [Related]
16. Pharmacophore design and database searching for selective monoamine neurotransmitter transporter ligands.
Macdougall IJ; Griffith R
J Mol Graph Model; 2008 Apr; 26(7):1113-24. PubMed ID: 18023378
[TBL] [Abstract][Full Text] [Related]
17. Analysis and optimization of structure-based virtual screening protocols. (3). New methods and old problems in scoring function design.
Smith R; Hubbard RE; Gschwend DA; Leach AR; Good AC
J Mol Graph Model; 2003 Sep; 22(1):41-53. PubMed ID: 12798390
[TBL] [Abstract][Full Text] [Related]
18. Discovery of novel PRL-3 inhibitors based on the structure-based virtual screening.
Park H; Jung SK; Jeong DG; Ryu SE; Kim SJ
Bioorg Med Chem Lett; 2008 Apr; 18(7):2250-5. PubMed ID: 18358718
[TBL] [Abstract][Full Text] [Related]
19. FlexE: efficient molecular docking considering protein structure variations.
Claussen H; Buning C; Rarey M; Lengauer T
J Mol Biol; 2001 Apr; 308(2):377-95. PubMed ID: 11327774
[TBL] [Abstract][Full Text] [Related]
20. Towards in silico lead optimization: scores from ensembles of protein/ligand conformations reliably correlate with biological activity.
Popov VM; Yee WA; Anderson AC
Proteins; 2007 Feb; 66(2):375-87. PubMed ID: 17078091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
